-
ABOUT USHebei Guangxiang Pharmaceutical Co., Ltd. is specializing in the production of bulk pharmaceuticals, fine pharmaceuticals, intermediate compounds and biopharmaceutical preparations.
-
News CenterAt the forefront of corporate development, we champion the positive energy of the Four Pharmaceutical Companies: fulfilling our duties conscientiously, stepping up to the plate and taking proactive action, embracing new missions, and conducting effective new publicity. In doing so, we aim to enhance the overall competence of our employees, stimulate their enthusiasm, initiative, and creativity, and provide robust ideological guidance and powerful spiritual strength to drive the enterprise forward.
-
INNOVATIONDevelops fine, series, high-end bulk pharmaceutical intermediates and innovative bulk pharmaceutical intermediates with high added value to build variety competition advantages.
-
-
RECRUITGuangxiang has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities.
-
CONTACTWith stable production, high-quality and reliable service, the company's products have been sold to more than 80 countries such as the United States, the United Kingdom, Germany and the Netherlands
Guangxiang Pharmaceutical of Shijiazhuang Sihua Pharmaceutical Group: Delivering a “Combination Punch” of Innovation to Seize the Initiative in Development
Category:
TIME：2022-04-20
【SUMMARY】
Its flagship product, caffeine, has seen robust growth across both production and sales; seven new specialty API products, including pentoxifylline and ornidazole, are poised for approval and market launch; and in the first quarter, its core business revenue posted triple-digit growth. Since the beginning of this year, Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, has delivered a powerful “combination punch,” securing a strong start to its innovative development.
Its flagship products, including caffeine, have seen robust growth across production and sales; seven new specialty API products, such as pentoxifylline and ornidazole, are poised for approval and market launch; and first-quarter core business revenue posted triple-digit growth... Since the beginning of this year, Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, has delivered a powerful “combination punch,” securing a strong start to its innovative development.
“Seizing opportunities and extending and strengthening our industrial chain has created new prospects for our development. The strong performance in the first quarter was, to a significant extent, driven by this acquisition. In early March, we acquired 100% of the equity in Cangzhou Lingang Youyi Chemical Co., Ltd., a leading domestic producer of methylamine-based products, which has given Guangxiang Pharmaceutical a powerful boost and added substantial weight to our competitive position in the market.” Speaking about this successful capital transaction, Cui Yongbin, Chairman of Guangxiang Pharmaceutical, said with enthusiasm that, as caffeine is a highly sought-after commodity in the international market, maintaining tight control over production costs is the key to sustained market success. Among the various cost components in caffeine production, monomethylamine accounts for a considerable share. By acquiring Youyi Chemical, which operates within the same industrial park, we have not only achieved notable reductions in caffeine production costs but have also effectively addressed the challenges of upstream–downstream integration and supply-chain coordination, thereby making our industrial chain more complete and efficient. This, in turn, has enhanced our influence and bargaining power in both domestic and international markets.
“Capital mergers and acquisitions have been commendable, but technological advancement has been equally indispensable; together, these efforts have solidified our core competitiveness,” said Cui Yongbin. Guangxiang Pharmaceutical serves as the strategic hub for Shisiyao Group’s initiative to establish an “API-plus-formulation” business model, accelerate industrial transformation, and strengthen and extend the industry value chain. The goal is to develop it into a new high ground for innovative, high-quality API development in China and to make it a core pillar of the industry’s growth. In recent years, leveraging research-and-development mechanisms such as the “challenge-based recruitment” system, Guangxiang Pharmaceutical has spearheaded collaborative efforts to tackle key core technologies in API production. Through flexible talent-introduction initiatives and with the support and guidance of research teams from Tsinghua University and Tianjin University, numerous common and critical technical challenges that had long constrained the yield and quality of its flagship product—caffeine—have been resolved, leading to a doubling of output and full-capacity operation. In the first quarter, the plant’s caffeine exports accounted for more than 30% of China’s total caffeine exports. Meanwhile, the efficiency of new-product R&D has also accelerated: seven new products—including pentoxifylline, ornidazole, levornidazole, and pitavastatin calcium—are expected to receive regulatory approval and enter commercial production in the near future, further highlighting the plant’s role as a model and driver of “specialized, refined, distinctive, and innovative” development and as a “little giant” enterprise.
Stepping into the production workshop of Guangxiang Pharmaceutical, one is met with state-of-the-art, modern, and intelligent equipment at every turn. “The promotion and application of advanced manufacturing equipment demonstrate our vision and confidence in aligning with international industry development. Since the beginning of this year, we have actively implemented digital information management and are committed to building an intelligent API manufacturing facility that meets world-class standards. By adopting new, intelligent polymorph-control technology, we can now precisely regulate product particle size and bulk density, thereby meeting the diverse requirements of high-end customers in Europe and North America. This has significantly improved flow properties for products such as caffeine and metronidazole, earning widespread trust from our customers,” said Cui Yongbin, speaking with evident pride. Through the introduction of cutting-edge, internationally advanced smart manufacturing equipment and core industrial software, coupled with deep integration and application, Guangxiang Pharmaceutical has achieved “one-button” control over the entire production process for its portfolio of products—including caffeine, theophylline, aminophylline, metronidazole, and nifedipine—bringing its scale and level of smart manufacturing to a leading position domestically. To date, Guangxiang Pharmaceutical has successively obtained national GMP certification as well as international certifications such as BRC, FSSC 22000, KOSHER, and HALAL, and has established strong cooperative relationships with major global caffeine purchasers.
“Going forward, we will leverage the policy opportunities presented by the national initiative to build a unified national market, continue to increase our investment in innovation, accelerate the implementation of new-product industrialization projects, use high-quality supply to create and lead demand, proactively develop forward-looking and industry-driving market initiatives, and steadily strengthen our appeal in both domestic and international markets,” Cui Yongbin said with full confidence.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
E-mail: hbgxzy@hebgxzy.com
Address: The west of Jingliu Road, lingang economic nad technological development zone, cangzhou city, Hebei province
Website
Official WeChat
e-Home
Business License
